Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares OutstandingShares Outstanding
Ratios

Tandem Diabetes Care (TNDM) Leases (2019 - 2026)

Tandem Diabetes Care filings provide 7 years of Leases readings, the most recent being $96.2 million for Q4 2025.

  • On a quarterly basis, Leases rose 12.74% to $96.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $96.2 million, a 12.74% increase, with the full-year FY2025 number at $96.2 million, up 12.74% from a year prior.
  • Leases hit $96.2 million in Q4 2025 for Tandem Diabetes Care, down from $98.4 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $126.7 million in Q2 2022 to a low of $15.1 million in Q1 2021.
  • Median Leases over the past 5 years was $90.2 million (2023), compared with a mean of $84.1 million.
  • Biggest five-year swings in Leases: surged 1249.23% in 2021 and later decreased 28.12% in 2023.
  • Tandem Diabetes Care's Leases stood at $27.5 million in 2021, then soared by 302.23% to $110.6 million in 2022, then decreased by 20.64% to $87.8 million in 2023, then dropped by 2.83% to $85.3 million in 2024, then grew by 12.74% to $96.2 million in 2025.
  • The last three reported values for Leases were $96.2 million (Q4 2025), $98.4 million (Q3 2025), and $98.4 million (Q2 2025) per Business Quant data.